Breast Cancer Clinical Trials in Philadelphia, Pennsylvania

35 studies are recruiting for breast cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

   This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07340541 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

4. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

   The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   64 in total

   Run by

   Genentech, Inc.

   See if you can join NCT07100106 on ClinicalTrials.gov

5. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

6. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

   This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   5 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07216105 on ClinicalTrials.gov

7. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia, Pennsylvania

   Locations

   14 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

8. PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

   This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse. Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Pa…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT02732171 on ClinicalTrials.gov

9. ATEMPT 2.0: Adjuvant T-DM1 vs TH

   This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   53 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04893109 on ClinicalTrials.gov

10. Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

    The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via th…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07737951 on ClinicalTrials.gov

11. Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

    This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Locations

    54 in total

    Run by

    University Hospital, Basel, Switzerland

    See if you can join NCT07140172 on ClinicalTrials.gov

12. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage

    Phase 3

    Ages

    18 to 100

    Site

    Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Locations

    179 in total

    Run by

    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov

13. Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

    The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Ai…

    Stage

    Not phased

    Ages

    45 to 74

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Locations

    13 in total

    Run by

    American College of Radiology

    See if you can join NCT05625659 on ClinicalTrials.gov

14. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #109, Philadelphia, Pennsylvania

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

15. Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors

    The goal of this study is to plan for a large scale evaluation of a program called Mindful After Cancer, or MAC. The MAC Program provides training in mindfulness, educational material about sexual health after cancer, and support to cancer survivors experiencing sexual and body image concerns. The …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    3 in total

    Run by

    Oregon State University

    See if you can join NCT07055854 on ClinicalTrials.gov

16. A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

    The MILES Study is a longitudinal, mixed-methods investigation of urinary biomarkers, energy balance, and lifestyle modifications in diverse women during early breast cancer treatment. The study's overarching goal is to assess dietary quality and physical activity changes over time using reliable, …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Abamson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT07655934 on ClinicalTrials.gov

17. ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

    This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio). This research study is testing whether using these drugs to target the disseminated tumor cel…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04523857 on ClinicalTrials.gov

18. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Rittenhouse Hematology/Oncology, Philadelphia, Pennsylvania

    Locations

    203 in total

    Run by

    Celcuity Inc

    See if you can join NCT06757634 on ClinicalTrials.gov

19. Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs

    The goal of this study is to find out whether a system that uses trained detection dogs and artificial intelligence (AI) can identify breast cancer from a person's breath. Women who are scheduled to have routine breast cancer screening, such as a mammogram, ultrasound, or a biopsy for a possible ca…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    6 in total

    Run by

    SpotitEarly

    See if you can join NCT07038785 on ClinicalTrials.gov

20. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pennsylvania (U Penn), Philadelphia, Pennsylvania

    Locations

    42 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

21. Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)

    The goal of this clinical trial is to study the safety, feasibility, histologic and immunological effects of Mitazalimab, a CD40 agonistic antibody, when administered either alone or in combination with PD-1 inhibition prior to surgical resection. The investigator hypothesizes that preoperative adm…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Jennifer Zhang

    See if you can join NCT07319195 on ClinicalTrials.gov

22. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacit…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04434040 on ClinicalTrials.gov

23. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania

    Locations

    15 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

24. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    7 in total

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04841148 on ClinicalTrials.gov

25. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania

    Locations

    14 in total

    Run by

    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov